TKIs are small molecules that can act intracellularly to inhibit multiple pathways involved in the pathogenesis of retinal diseases and when combined with the appropriate sustained delivery platform may offer a more durable treatment approach, ultimately reducing the treatment burden for patients.
German biotechnology company Isarna Therapeutics has reported favorable results from its phase 2 BETTER trial of ISTH0036, an experimental antisense therapy targeting transforming growth factor beta-2 (TGF-β2), in patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). The data were presented May 6 at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Salt Lake City, Utah.
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.